Therapeutic formulation and methods of treatment

摘要

The present disclosure relates pharmaceutical formulations comprising hydralazine in the treatment of eye diseases and conditions with the formulations. The present disclosure also related to methods of preparing the pharmaceutical formulations.

主权项

1. An ophthalmic composition, consisting essentially of:
a pharmaceutically active drug comprising hydralazine in an amount between about 0.02-2 wt %; an acetate buffer solution having pH of between 3.9-4.5 in an amount between 8-12 wt %; propylene glycol in an amount between 0.5-2 wt %; sodium chloride in an amount between 0.25-1 wt %; methylparaben in an amount between 0.015-0.06 wt %; benzalkonium chloride in the form of a 50% solution, present in an amount between 0.01-0.04 wt %; and edetate disodium in an amount between 0.008-0.030 wt %; wherein said composition has a pH of between 4.0-4.4; wherein a decrease in the w/w % of the active drug is less than about 10% after one month storage.